Morning Session
Afternoon Session
8:30 AM - 9:00 AM
Registration and Breakfast
9:00 AM - 9:10 AM
Welcome and Introduction
9:10 AM - 9:50 AM
KEYNOTE: Radioligand Therapy for Solid Tumours:
From PSMA‑Targeted Agents to Novel Radiopharmaceuticals
9:50 AM - 10:20 AM
The Future of ADCs: Advancing Payloads, Linkers, and Next-Generation Technologies
10:20 AM - 10:50 AM
Virtual Nurse Navigator Program for Clinical Trials: Improving Access & Patient Experience
10:50 AM - 11:05 AM
Panel Discussion
11:05 AM - 11:20 AM
Break
11:20 AM -11:40 AM
DEBATE: FOR
Phase 1 trials should be offered upfront as a standard care option
—not a last resort— for patients with advanced cancer
11:40 AM -12:00 PM
DEBATE: AGAINST
Phase 1 trials should be offered upfront as a standard care option
—not a last resort— for patients with advanced cancer
12:00 PM -12:05 PM
Debate Rebuttal: FOR
12:05 PM -12:10 PM
Debate Rebuttal: AGAINST
1:00 PM - 1:40 PM
KEYNOTE: Induced proximity therapeutics for targeted protein degradation and beyond
1:40 PM - 2:10 PM
AIRCHECK —> From Data to Binders: AIRCHECK for AI-Driven Protein–Ligand Discovery
2:10 PM - 2:25 PM
Panel Discussion
2:25 PM - 2:40 PM
Break
2:40 PM - 3:10 PM
ctDNA in Early‑Phase Trials: Feasibility, Sensitivity, and How It Can Guide Go/No‑Go Decisions
3:10 PM - 3:40 PM
Next-Gen KRAS inhibitors - Beyond G12C into Pan‑KRAS & Multi‑Mutant Approaches
3:40 PM - 3:55 PM
Panel Discussion
3:55 PM - 4:00 PM
Closing Remarks
© Drug Development Program – Phase 1 | Princess Margaret Cancer Centre, UHN. All Rights Reserved.